28 Organizations Ask President Obama to Support Colombian Compulsory License on Expensive Leukemia Drug

Contact:
(U.S.) Andrew Goldman, KEI: andrew.goldman@keionline.org or +1 (202) 332-2670
(Colombia) Andrea Carolina Reyes Rojas, Misión Salud: subdireccion@mision-salud.org
(Colombia) Dr. Francisco Rossi, IFARMA: francisco_rossi@hotmail.com

(More on Colombia here: /colombia)

Washington, DC — Today, 28 organizations that support the advancement of public health, as well as the successful continuation of the peace process in Colombia, urged President Obama to voice U.S. support for Colombia’s right to grant a compulsory license on an expensive leukemia drug. Continue Reading

Uncategorized

HAI/KEI intervention at the WHA69 on the negotiations on an R&D agreement

Jamie-740x.jpg The following is the intervention on behalf of Stichting Health Action International (HAI) at 69th World Health Assembly, Agenda Item 16.2: Follow-up to the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination – Report of the open-ended meeting of Member States.

KEI worked with HAI on the statement, and it was delivered by James Love


Continue Reading

Uncategorized

Sens. Sherrod Brown and Bernie Sanders send letter to USTR condemning pressure on Colombia compulsory license for cancer drug

(More on Colombia here: /colombia)

In response to reports of USTR pressure on Colombia’s potential compulsory license for imatinib, Senators Sherrod Brown, D-Ohio, and Bernie Sanders, I-Vt., have sent a letter to USTR objecting “to any efforts to protect the public health of Colombians in a way that is appropriate, effective, and consistent with the country’s trade and public health obligations,” and condemning as unconscionable “that any representatives of the U.S. government would threaten to rescind funding for Colombia’s peace iniative if a compulsory license for Glivec were issued.” Continue Reading

WHA 69: Colombian Minister of Health Calls on WHO to Support the Regulation of Drug Monopolies

(More on Colombia here: /colombia)

On May 24, 2016, Colombia’s Minister of Health, Alejandro Gaviria, made an intervention at the World Health Assembly that referred to the pressure Colombia has been facing with regard to the potential compulsory license for imatinib and called for the WHO to support members to ensure sustainable development through the regulation of pharmaceutical monopolies and promoting competition, transparency, and the rational use of drugs.
Continue Reading

Uncategorized

Letter from KEI, Public Citizen, Oxfam America and Health GAP to Senator Hatch, regarding Colombia Compulsory License

Attached is a letter that KEI, Public Citizen, Oxfam America and Health GAP have sent to Senator Hatch, via the Senate Finance Committee, objecting to the pressure his office has put on Colombia over a compulsory license on patents held by Novartis for the cancer drug Gleevec. This refers to the accounts of pressure from Hatch’s office that are described in two letters from the Colombia Embassy in Washington, dated April 27 and April 28, which were recently leaked. Continue Reading